Clinical trials
Phase 1 Leukemia, Lymphocytic, Chronic, B-Cell trials in Poland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2011 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Recruiting | 4 |
| Terminated | 4 |
| Active, not recruiting | 2 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Janssen Research & Development, LLC | 6 |
| Hoffmann-La Roche | 2 |
| Hutchmed | 2 |
| Acerta Pharma BV | 1 |
| Eli Lilly and Company | 1 |
| Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 1 |
| MedImmune LLC | 1 |
| Nurix Therapeutics, Inc. | 1 |
| Prelude Therapeutics | 1 |
| Schrödinger, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 19 |
| Lymphoma, Non-Hodgkin | 11 |
| Lymphoma, B-Cell, Marginal Zone | 6 |
| Lymphoma, Mantle-Cell | 6 |
| Waldenstrom Macroglobulinemia | 5 |
| Lymphoma, Follicular | 4 |
| Lymphoma | 3 |
| Lymphoma, Large B-Cell, Diffuse | 3 |
| Leukemia | 2 |
| Leukemia, Myeloid, Acute | 2 |
Trials
Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.